These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27628006)

  • 1. Anticoagulation Therapy in Patients with Chronic Kidney Disease.
    Saheb Sharif-Askari F; Syed Sulaiman SA; Saheb Sharif-Askari N
    Adv Exp Med Biol; 2017; 906():101-114. PubMed ID: 27628006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.
    Sciascia S; Radin M; Schreiber K; Fenoglio R; Baldovino S; Roccatello D
    Intern Emerg Med; 2017 Dec; 12(8):1101-1108. PubMed ID: 28929298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bridging: Perioperative management of chronic anticoagulation or antiplatelet therapy].
    Nowak-Göttl U; Langer F; Limperger V; Mesters R; Trappe RU
    Dtsch Med Wochenschr; 2014 Jun; 139(24):1301-6. PubMed ID: 24892468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Sailing in troubled waters': a review of the use of anticoagulation in adult cancer patients with thrombocytopenia.
    Ibrahim RB; Skewes MD; Kuriakose P
    Blood Coagul Fibrinolysis; 2016 Sep; 27(6):615-30. PubMed ID: 26945262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of current and emerging antithrombotics in thrombosis and cancer.
    Mousa SA
    Drugs Today (Barc); 2006 May; 42(5):331-50. PubMed ID: 16801996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SR123781A, a synthetic heparin mimetic.
    Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
    Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Heparins].
    Marbet GA
    Ther Umsch; 2003 Jan; 60(1):10-3. PubMed ID: 12638471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety of heparins in end-stage renal disease.
    Sonawane S; Kasbekar N; Berns JS
    Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse outcomes of anticoagulant use among hospitalized patients with chronic kidney disease: a comparison of the rates of major bleeding events between unfractionated heparin and enoxaparin.
    Saheb Sharif-Askari F; Syed Sulaiman SA; Saheb Sharif-Askari N; Al Sayed Hussain A; Railey MJ
    PLoS One; 2014; 9(9):e106517. PubMed ID: 25181525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Hirsh J; Bauer KA; Donati MB; Gould M; Samama MM; Weitz JI
    Chest; 2008 Jun; 133(6 Suppl):141S-159S. PubMed ID: 18574264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet Agents and Anticoagulants in Patients with Chronic Kidney Disease - from Pathophysiology to Clinical Practice.
    Lutz J; Jurk K
    Curr Pharm Des; 2017; 23(9):1366-1376. PubMed ID: 27917715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation in patients with impaired renal function and with haemodialysis. Anticoagulant effects, efficacy, safety, therapeutic options.
    Harenberg J; Hentschel VA; Du S; Zolfaghari S; Krämer R; Weiss C; Krämer BK; Wehling M
    Hamostaseologie; 2015; 35(1):77-83. PubMed ID: 25405246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency.
    Park D; Southern W; Calvo M; Kushnir M; Solorzano C; Sinnet M; Billett HH
    J Gen Intern Med; 2016 Feb; 31(2):182-187. PubMed ID: 26209179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation and reinitiation of anticoagulation therapy.
    Witt DM
    Semin Hematol; 2011 Oct; 48(4):295-301. PubMed ID: 22000095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A guide to the use of anticoagulant drugs in children.
    Law C; Raffini L
    Paediatr Drugs; 2015 Apr; 17(2):105-14. PubMed ID: 25711916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bridging anticoagulation].
    Schellong SM; Halbritter K; Haas S
    Chirurg; 2007 Feb; 78(2):125-6, 128-32. PubMed ID: 17252252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5?
    Yildirim T; Kocak T; Buyukasik Y; Yilmaz R; Altun B; Erdem Y; Arici M
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):700-4. PubMed ID: 23135378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.